SGLT2 inhibitors were originally developed to lower blood glucose in people with type 2 diabetes. Today, their role has become much broader.
Large clinical trials have shown that these medicines can protect the heart and kidneys in people at increased cardiovascular or kidney risk. Importantly, some of these benefits are also seen in people without diabetes.
This has led to a new question in longevity medicine:
Could SGLT2 inhibitors help people age healthier?
The answer depends on what we mean by healthy aging.
From Diabetes Drugs to Heart and Kidney Protection
SGLT2 inhibitors work partly by increasing the amount of glucose and sodium eliminated through the kidneys.
But their clinical effects extend well beyond lowering blood sugar.
Research has shown that SGLT2 inhibitors can reduce the risk of heart failure events and slow the progression of chronic kidney disease in appropriately selected patients.
These benefits are particularly important because heart failure and chronic kidney disease become increasingly common with age and can have a major effect on independence, physical function and survival.
Protecting these organs may therefore have consequences that extend far beyond treating a single disease.
The Benefits Are Not Limited to People With Diabetes
This is one of the most important developments in our understanding of SGLT2 inhibitors.
Large randomized clinical trials and subsequent meta-analyses have found heart and kidney benefits not only in people with type 2 diabetes, but also in selected patients without diabetes who already have conditions such as heart failure or chronic kidney disease.
This tells us something important.
The protective effects of SGLT2 inhibitors cannot be explained simply by better glucose control.
They appear to influence several physiological processes involved in cardiovascular and kidney function.
What Does This Have to Do With Healthy Aging?
Healthy aging is not only about changing a laboratory marker of biological age.
It is also about delaying diseases that reduce healthspan — the years of life spent in good health and with preserved function.
Cardiovascular disease, heart failure and chronic kidney disease are major contributors to illness and disability later in life.
If a treatment can meaningfully reduce the progression or complications of these conditions, it may help preserve health for longer.
In this sense, SGLT2 inhibitors could contribute to healthier aging indirectly through disease and organ protection.
That is different from proving that they directly slow the biological aging process.
Are SGLT2 Inhibitors Anti-Aging Drugs?
Not based on current evidence.
There is growing scientific interest in the biological effects of SGLT2 inhibition beyond the heart and kidneys. Experimental research has explored possible effects on inflammation, cellular energy metabolism, oxidative stress and other pathways associated with aging.
These findings provide an interesting biological rationale for further research.
But we do not yet have evidence that SGLT2 inhibitors slow biological aging or extend lifespan in healthy people.
Their strongest evidence remains clinical: protecting the heart and kidneys in people who have medical conditions or risk profiles for which these treatments have demonstrated benefit.
Should Healthy People Take Them for Longevity?
At present, there is no established evidence supporting routine SGLT2 inhibitor treatment in healthy people simply to promote longevity.
The fact that benefits can occur without diabetes does not mean that everyone without diabetes is likely to benefit.
The participants in major clinical trials generally had heart failure, chronic kidney disease or another defined cardiovascular or renal risk.
That distinction matters.
SGLT2 inhibitors are prescription medicines and can also cause adverse effects. Their use should therefore be based on an individual’s medical condition, expected benefit and potential risk — not simply on the idea that a medicine might influence aging.
A Different Way to Think About Longevity Medicine
The SGLT2 story illustrates an important principle.
A medicine does not have to be proven to slow the molecular mechanisms of aging to make a meaningful contribution to healthspan.
Preventing heart failure progression, preserving kidney function and reducing serious cardiovascular complications can help people remain healthier for longer.
For people who already have an appropriate medical indication, SGLT2 inhibitors may therefore do more than treat one disease.
They may help protect some of the organ systems that are particularly important for maintaining health as we age.
Based on Research
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. The Lancet, 2022; 400(10365):1788–1801.
https://pubmed.ncbi.nlm.nih.gov/36351458/
